Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib alone or with pembrolizumab with or without platinum-pemetrexed in untreated KRAS G12C-mutant advanced non-small cell lung cancer
NL-OMON59566Phase 2Recruiting
- Sponsor
- Roche
- Start
- Aug 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of divarasib, pembrolizumab, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Roche. Primary endpoints: Occurrence of adverse events and Change from baseline in targeted safety parameters. Started Aug 2023; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59566.